{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:09:01Z","timestamp":1790665741729,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":440,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head Neck"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1002\/hed.23664","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T09:39:08Z","timestamp":1394012348000},"page":"722-726","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial"],"prefix":"10.1002","volume":"37","author":[{"given":"Andrew C.","family":"Hoover","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Milhem","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carryn M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Buatti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology; University of Iowa Hospitals and Clinics; Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,18]]},"reference":[{"key":"10.1002\/hed.23664-BIB0001|hed23664-cit-0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1054\/bjps.2001.3636","article-title":"Adenoid cystic carcinoma of the head and neck","volume":"54","author":"Chummun","year":"2001","journal-title":"Br J Plast Surg"},{"key":"10.1002\/hed.23664-BIB0002|hed23664-cit-0002","volume-title":"SEER Survival Monograph: Cancer survival among adults: US SEER Program, 1988-2001, patient and tumor characteristics","year":"2007"},{"key":"10.1002\/hed.23664-BIB0003|hed23664-cit-0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.1013","article-title":"Adenoid cystic carcinoma: a retrospective clinical review","volume":"96","author":"Khan","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1002\/hed.23664-BIB0004|hed23664-cit-0004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.oraloncology.2006.01.001","article-title":"Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies","volume":"42","author":"Dodd","year":"2006","journal-title":"Oral Oncol"},{"key":"10.1002\/hed.23664-BIB0005|hed23664-cit-0005","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4161\/cbt.8.20.9596","article-title":"Signaling pathways in adenoid cystic cancers: implications for treatment","volume":"8","author":"Gupta","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1002\/hed.23664-BIB0006|hed23664-cit-0006","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2009.03.004","article-title":"Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT","volume":"74","author":"Gupta","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1002\/hed.23664-BIB0007|hed23664-cit-0007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinthera.2006.05.011","article-title":"Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir\/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study","volume":"28","author":"Gathe","year":"2006","journal-title":"Clin Ther"},{"key":"10.1002\/hed.23664-BIB0008|hed23664-cit-0008","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0 http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf 2013"},{"key":"10.1002\/hed.23664-BIB0009|hed23664-cit-0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1002\/hed.23664-BIB0010|hed23664-cit-0010","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1002\/hed.23664-BIB0011|hed23664-cit-0011","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1086\/515312","article-title":"A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection","volume":"177","author":"Markowitz","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1002\/hed.23664-BIB0012|hed23664-cit-0012","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir \/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"10.1002\/hed.23664-BIB0013|hed23664-cit-0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/1973947812Y.0000000011","article-title":"Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells","volume":"24","author":"Sun","year":"2012","journal-title":"J Chemother"},{"key":"10.1002\/hed.23664-BIB0014|hed23664-cit-0014","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1742-4658.2012.08619.x","article-title":"Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer","volume":"279","author":"Guan","year":"2012","journal-title":"FEBS J"},{"key":"10.1002\/hed.23664-BIB0015|hed23664-cit-0015","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-10-3216","article-title":"Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6","volume":"17","author":"Guan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1002\/hed.23664-BIB0016|hed23664-cit-0016","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","article-title":"The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo","volume":"97","author":"Bono","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/hed.23664-BIB0017|hed23664-cit-0017","doi-asserted-by":"crossref","first-page":"29408","DOI":"10.1074\/jbc.M110.197665","article-title":"Modulation of CCAAT\/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"286","author":"Tian","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1002\/hed.23664-BIB0018|hed23664-cit-0018","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr2602","article-title":"Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells","volume":"12","author":"Br\u00fcning","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1002\/hed.23664-BIB0019|hed23664-cit-0019","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/QAI.0b013e3181aa13c7","article-title":"The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients","volume":"51","author":"Crum-Cianflone","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1002\/hed.23664-BIB0020|hed23664-cit-0020","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/hed.23664-BIB0021|hed23664-cit-0021","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JTO.0b013e3182435aa6","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB non-small cell lung cancer: a report of toxicities and clinical response","volume":"7","author":"Rengan","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1002\/hed.23664-BIB0022|hed23664-cit-0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11523-011-0176-7","article-title":"Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs","volume":"6","author":"Ogita","year":"2011","journal-title":"Target Oncol"},{"key":"10.1002\/hed.23664-BIB0023|hed23664-cit-0023","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1002\/hed.23664-BIB0024|hed23664-cit-0024","doi-asserted-by":"crossref","first-page":"371","DOI":"10.18632\/oncotarget.477","article-title":"Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"10.1002\/hed.23664-BIB0025|hed23664-cit-0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","article-title":"Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma","volume":"33","author":"Hill","year":"1997","journal-title":"Oral Oncol"}],"container-title":["Head & Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.23664","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hed.23664\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T02:46:09Z","timestamp":1625280369000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.23664"}},"subtitle":["Nelfinavir monotherapy in refractory adenoid cystic carcinoma"],"short-title":[],"issued":{"date-parts":[[2014,6,18]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"URL":"https:\/\/doi.org\/10.1002\/hed.23664","relation":{},"ISSN":["1043-3074"],"issn-type":[{"value":"1043-3074","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6,18]]}}}